Vimta Labs (524394) Q3 24/25 earnings summary

Executive summary

• Revenue for Q3 FY25 rose to INR 899.23 million (consolidated), up from INR 745.82 million in Q3 FY24; nine-month revenue reached INR 2,495.41 million, up from INR 2,158.62 million year-over-year.

• Net profit for Q3 FY25 (consolidated) was INR 214.96 million, compared to INR 101.32 million in Q3 FY24; nine-month net profit was INR 490.23 million, up from INR 286.58 million year-over-year.

• Discontinued operations contributed a one-time post-tax gain of INR 45.15 million in Q3 FY25 due to the sale of the Diagnostic and Pathological services business.

Financial highlights

• Consolidated EBITDA for Q3 FY25 improved, with profit before tax at INR 239.16 million, up from INR 156.41 million in Q3 FY24.

• Earnings per share (EPS) from continuing and discontinued operations for Q3 FY25 was INR 9.65 (basic), up from INR 4.57 in Q3 FY24.

• Total comprehensive income for Q3 FY25 (consolidated) was INR 214.90 million, compared to INR 101.26 million in Q3 FY24.

• Standalone revenue for Q3 FY25 was INR 885.18 million, with net profit at INR 210.19 million.

Outlook and guidance

• The amalgamation of EMTAC Laboratories Private Limited with Vimta Labs is in process, with NCLT exemption granted for shareholder and creditor meetings; no impact on current financials.

• The company expects recurring royalty income from the divested Diagnostic and Pathological services business for at least two years.